Several factors can increase the risk of drug-induced proarrhythmia. These include patient-specific factors like genetic predisposition, electrolyte imbalances, and pre-existing heart conditions. Additionally, the pharmacokinetics of the drug, such as half-life and metabolic pathways, can influence proarrhythmic risk. Drug interactions that affect the metabolism or excretion of antiarrhythmic drugs can also contribute to this risk, as can the concomitant use of other medications that prolong the QT interval.
